参考文献/References:
[1] 彭珏. 乳腺癌,全球诊断人数最多的癌症[J]. 江苏卫生保健,2021(4):19.
[2] Leemasawat K,Phrommintikul A,Chattipakorn SC,et al. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs:insights from in vitro,in vivo,and clinical studies in breast cancer patients[J]. Cell Mol Life Sci,2020,77(8):1571-1589.
[3] Fedele C,Riccio G,Malara AE,et al. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors[J]. Breast Cancer Res Treat,2012,134(2):595-602.
[4] B?ker C,von Figura K,Hille-Rehfeld A. The carboxy-terminal peptides of 46 kDa and 300 kDa mannose 6-phosphate receptors share partial sequence homology and contain information for sorting in the early endosomal pathway[J]. J Cell Sci,1997,110(Pt 8):1023-1032.
[5] Caron J,Nohria A. Cardiac toxicity from breast cancer treatment:can we avoid this?[J]. Curr Oncol Rep,2018,20(8):61.
[6] Chu CH,Tzang BS,Chen LM,et al. IGF-Ⅱ/mannose-6-phosphate receptor signaling induced cell hypertrophy and atrial natriuretic peptide/BNP expression via Galphaq interaction and protein kinase C-α/CaMKⅡ activation in H9c2 cardiomyoblast cells[J]. J Endocrinol,2008,197(2):381-390.
[7] Leroith D,Holly JMP,Forbes BE. Insulin-like growth factors:ligands,binding proteins,and receptors[J]. Mol Metab,2021,52:101245.
[8] Huang CY,Hao LY,Buetow DE. Hypertrophy of cultured adult rat ventricular cardiomyocytes induced by antibodies against the insulin-like growth factor (IGF)-Ⅰ or the IGF-Ⅰ receptor is IGF-Ⅱ-dependent[J]. Mol Cell Biochem,2002,233(1-2):65-72.
[9] Chen Z,Ge Y,Kang JX. Down-regulation of the M6P/IGF-Ⅱreceptor increases cell proliferation and reduces apoptosis in neonatal rat cardiac myocytes[J]. BMC Cell Biol,2004,5:15.
[10] Lee SD,Chu CH,Huang EJ,et al. Roles of insulin-like growth factor Ⅱ in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation[J]. Am J Physiol Endocrinol Metab,2006,291(2):E306-E314.
[11] 陈元元,范晓晨. 胰岛素样生长因子受体在病毒性心肌炎小鼠心肌中的表达[J]. 广东医学,2015,36(6):832-835.
[12] Chu CH,Tzang BS,Chen LM,et al. Activation of insulin-like growth factor Ⅱ receptor induces mitochondrial-dependent apoptosis through Gαq and downstream calcineurin signaling in myocardial cells[J]. Endocrinology,2009,150(6):2723-2731.
[13] Huang CY,Lai CH,Kuo CH,et al. Inhibition of ERK-Drp1 signaling and mitochondria fragmentation alleviates IGF-ⅡR-induced mitochondria dysfunction during heart failure[J]. J Mol Cell Cardiol,2018,122:58-68.
[14] Huang CY,Kuo WW,Yeh YL,et al. ANGⅡ promotes IGF-ⅡR expression and cardiomyocyte apoptosis by inhibiting HSF1 via JNK activation and SIRT1 degradation[J]. Cell Death Differ,2014,21(8):1262-1274.
[15] Huang CY,Pai PY,Kuo CH,et al. p53-mediated miR-18 repression activates HSF2 for IGF-ⅡR-dependent myocyte hypertrophy in hypertension-induced heart failure[J]. Cell Death Dis,2017,8(8):e2990.
[16] Huang CY,Kuo CH,Pai PY,et al. Inhibition of HSF2 SUMOylation via MEL18 upregulates IGF-ⅡR and leads to hypertension-induced cardiac hypertrophy[J]. Int J Cardiol,2018,257:283-290.
[17] Uriarte-Pinto M,Escolano-Pueyo ?,Gimeno-Ballester V,et al. Trastuzumab,non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer[J]. Int J Clin Pharm,2016,38(2):446-453.
[18] Huang CY,Kuo WW,Lo JF,et al. Doxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-ⅡR-dependent cardiomyocyte death[J]. Cell Death Dis,2016,7(11):e2455.
[19] Keefe DL. Trastuzumab-associated cardiotoxicity[J]. Cancer,2002,95(7):1592-1600.
[20] Nicolazzi MA,Carniceelli A,Fuorlo M,et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer[J]. Eur Rev Med Pharmacol Sci,2018,22(7):2175-2185.
[21] Zamorano JL,Lancellotti P,Mu?oz DR,et al. [2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines][J]. Kardiol Pol,2016,74(11):1193-1233.
[22] Wu Q,Bai B,Tian C,et al. The molecular mechanisms of cardiotoxicity induced by HER2,VEGF,and tyrosine kinase inhibitors:an updated review[J]. Cardiovasc Drugs Ther,2022,36(3):511-524.
[23] Gordon LI,Burke MA,Singh AT,et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways[J]. J Biol Chem,2009,284(4):2080-2087.
[24] Hedhli N,Huang Q,Kalinowski A,et al. Endothelium-derived neuregulin protects the heart against ischemic injury[J]. Circulation,2011,123(20):2254-2262.
[25] Shirmard LR,Shabani M,Moghadam AA,et al. Protective effect of curcumin,chrysin and thymoquinone injection on trastuzumab-induced cardiotoxicity via mitochondrial protection[J]. Cardiovasc Toxicol,2022,22(7):663-675.
[26] Kabel AM,Elkhoely AA. Targeting proinflammatory cytokines,oxidative stress,TGF-β1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity[J]. Biomed Pharmacother,2017,93:17-26.
[27] Sasaki R,Kurebayashi,Eguchi H,et al. Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity[J]. Cancer Sci,2022,113(10):3449-3462.
[28] Sun L,Wang H,Yu S,et al. Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2?cells[J]. Int J Mol Med,2022,49(2):17.
[29] Ye T,Yang W,Gao T,et al. Trastuzumab-induced cardiomyopathy via ferroptosis-mediated mitochondrial dysfunction[J]. Free Radic Biol Med,2023,206:143-161.
[30] Hou H,Xu Y,Xie M,et al. Exploring the potential molecular mechanism of trastuzumab-induced cardiotoxicity based on RNA sequencing and bioinformatics analysis[J]. Biochem Pharmacol,2023,208:115388.
相似文献/References:
[1]董新江 尚茹茹 刘晓红.乳腺癌放化疗引起心脏毒性的一级预防进展[J].心血管病学进展,2020,(1):78.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.021]
DONG Xinjiang,SHANG Ruru,?LIU Xiaohong.Primary Prevention of Cardiotoxicity Caused by Radiotherapy and Chemotherapy for Breast Cancer[J].Advances in Cardiovascular Diseases,2020,(1):78.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.021]
[2]布热比古力·阿布力米提 付真彦.乳腺癌药物治疗与心肌损伤[J].心血管病学进展,2020,(8):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
Burebiguli·abulimitiFU Zhenyan.Drug Therapy of Breast Cancer and Assosiated Myocardial Damage[J].Advances in Cardiovascular Diseases,2020,(1):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
[3]戴秋月 郎吉萍 吕萍 潘杭雨 郭志刚.他汀类药物抗乳腺癌作用的研究进展[J].心血管病学进展,2021,(9):776.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
DAI Qiuyue,LANG Jiping,LYU Ping,et al.Effect of Statins Against Breast Cancer[J].Advances in Cardiovascular Diseases,2021,(1):776.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[4]赵恒 谭琦 杜晓宇 谷泽慧 王亚帝.蒽环类药物致心脏毒性潜在的生物标志物研究[J].心血管病学进展,2022,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
ZHAO HengTAN QiDU XiaoyuGU ZehuiWANG Yadi.Potential Biomarkers of Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2022,(1):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[5]郭良 黄鹤.恶性肿瘤相关心房颤动发病机制的研究进展[J].心血管病学进展,2022,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.002]
GUO LiangHUANG He.Pathogenesis of Malignant Tumor-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(1):870.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.002]
[6]杨仙 陈芸霖 殷跃辉 易鑫 杨敏 崔犇.女性乳腺癌相关性心房颤动的研究现状[J].心血管病学进展,2023,(8):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]
YANG Xian,CHEN Yunlin,YIN Yuehui,et al.Research Status of Female Breast Cancer Associated Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(1):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]